Clinical Trials

Right-to-Try Use of ERC1671 to Treat Glioblastoma Multiforme (GBM) When Given in Combination with GM-CSF, Cyclophosphamide, Bevacizumab and Nivolumab in Patients who have Failed Prior Treatment with Radiation and Temozolomide


Study ID
ERC-RTT-Right to Try- Pro2019-0295-

NCT Number
(Click on the NCT number for more information about the trial)

Research Study Number
2019-0295

Principle Investigator
Dr. Samuel Singer

Sponsor
Epitopoietic Research Corporation


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now